Camylofin

Camylofin Chlorhydrate (CAS No.: 54-30-8) is a synthetic small molecule generally classified in pharmacological research as an antimuscarinic anticholinergic smooth muscle relaxant and is primarily used as a reference compound in studies of visceral smooth muscle regulation, cholinergic neurotransmission, and spasmolytic mechanism profiling in biomedical discovery settings; functionally, it is investigated for its capacity to reduce muscarinic receptor mediated contractile signaling in smooth muscle systems, with mechanism level interpretations commonly centered on attenuation of acetylcholine driven pathways that involve G protein coupled receptor activation, phospholipase C linked second messenger generation, and downstream intracellular calcium dependent contraction processes, while some assay contexts also evaluate potential contributions from direct myotropic effects on contractile tone, requiring model specific confirmation; because publicly standardized potency datasets are limited and assay conditions vary substantially across tissue preparations and receptor subtype systems, reported in vitro activity is typically interpreted within broad concentration windows from micromolar to low millimolar testing ranges rather than a single universally accepted IC50 or EC50 benchmark, and compound performance is therefore best compared using internally controlled assay platforms; in life sciences workflows, Camylofin Chlorhydrate is commonly applied in receptor pharmacology panels, isolated tissue contractility assays, calcium flux or organ bath studies, and exploratory preclinical models of smooth muscle hypercontractility to support hit to lead benchmarking, mechanism deconvolution, and translational hypothesis generation, with concentrations or doses used in experiments typically depending on specific experimental designs and research objectives.